A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure

NCT00894699 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Sedation
Anxiety
Pain

Interventions

DRUG: Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)
DRUG: Placebo NanoTab™

Sponsor

Talphera, Inc